Neuronal Death in the Contralateral Un-Injured Retina after Unilateral Axotomy: Role of Microglial Cells.
bilateral response
meloxicam
minocycline
optic nerve crush
retinal ganglion cells (RGC)
visual system
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
15 Nov 2019
15 Nov 2019
Historique:
received:
11
10
2019
revised:
12
11
2019
accepted:
13
11
2019
entrez:
17
11
2019
pubmed:
17
11
2019
medline:
9
4
2020
Statut:
epublish
Résumé
For years it has been known that unilateral optic nerve lesions induce a bilateral response that causes an inflammatory and microglial response in the contralateral un-injured retinas. Whether this contralateral response involves retinal ganglion cell (RGC) loss is still unknown. We have analyzed the population of RGCs and the expression of several genes in both retinas of pigmented mice after a unilateral axotomy performed close to the optic nerve head (0.5 mm), or the furthest away that the optic nerve can be accessed intraorbitally in mice (2 mm). In both retinas, RGC-specific genes were down-regulated, whereas caspase 3 was up-regulated. In the contralateral retinas, there was a significant loss of 15% of RGCs that did not progress further and that occurred earlier when the axotomy was performed at 2 mm, that is, closer to the contralateral retina. Finally, the systemic treatment with minocycline, a tetracycline antibiotic that selectively inhibits microglial cells, or with meloxicam, a non-steroidal anti-inflammatory drug, rescued RGCs in the contralateral but not in the injured retina. In conclusion, a unilateral optic nerve axotomy triggers a bilateral response that kills RGCs in the un-injured retina, a death that is controlled by anti-inflammatory and anti-microglial treatments. Thus, contralateral retinas should not be used as controls.
Identifiants
pubmed: 31731684
pii: ijms20225733
doi: 10.3390/ijms20225733
pmc: PMC6888632
pii:
doi:
Substances chimiques
Minocycline
FYY3R43WGO
Meloxicam
VG2QF83CGL
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Instituto de Salud Carlos III
ID : PI16/00031; RD16/0008/0026
Organisme : Spanish Ministry of Economy and Competitiveness
ID : SAF2015-67643-P,
Organisme : Fundación Séneca
ID : 19881/GERM/15
Références
Front Neuroanat. 2014 Oct 06;8:99
pubmed: 25339868
Vision Res. 2009 Jan;49(1):115-26
pubmed: 18952118
Brain Res. 2001 Aug 3;909(1-2):187-93
pubmed: 11478935
Invest Ophthalmol Vis Sci. 2009 Aug;50(8):3860-8
pubmed: 19264888
Neurosci Lett. 2015 Mar 30;591:105-9
pubmed: 25700948
Exp Eye Res. 2015 May;134:47-52
pubmed: 25797477
Curr Biol. 2019 Apr 1;29(7):1149-1160.e4
pubmed: 30905607
PLoS One. 2012;7(11):e49830
pubmed: 23166779
J Vis Exp. 2011 May 12;(51):
pubmed: 21610673
J Neuroinflammation. 2019 Feb 18;16(1):43
pubmed: 30777091
J Neurophysiol. 2016 Jun 1;115(6):3018-29
pubmed: 26984426
Cancer Res. 2004 Aug 1;64(15):5245-50
pubmed: 15289330
J Comp Neurol. 2014 Apr 15;522(6):1411-43
pubmed: 24318667
Exp Brain Res. 1988;71(3):611-7
pubmed: 3416972
J Comp Neurol. 1980 Jun;191(3):383-412
pubmed: 7410600
J Neurosci. 1994 Jul;14(7):4368-74
pubmed: 8027784
Brain Res Bull. 2006 Dec 11;71(1-3):208-18
pubmed: 17113948
Neurosci Lett. 2009 Aug 28;460(2):121-5
pubmed: 19450656
Exp Eye Res. 2013 Mar;108:84-93
pubmed: 23295345
Science. 1965 Sep 24;149(3691):1506-7
pubmed: 17791642
Int J Neurosci. 2011 Mar;121(3):142-8
pubmed: 21138398
Neuroscience. 2015 Dec 17;311:56-66
pubmed: 26432953
Optom Vis Sci. 2005 Sep;82(9):850-7
pubmed: 16189496
Invest Ophthalmol Vis Sci. 2016 Jan 1;57(1):81-93
pubmed: 26780312
Neurosci Lett. 1996 Oct 25;218(1):1-4
pubmed: 8939466
J Neurosci. 1988 Jan;8(1):265-80
pubmed: 2448429
J Comp Neurol. 1980 Feb 15;189(4):711-20
pubmed: 7381047
J Neurosci. 2001 Apr 15;21(8):2580-8
pubmed: 11306611
Mol Vis. 2008 Aug 22;14:1540-8
pubmed: 18728752
J Neuroinflammation. 2014 Jan 08;11:3
pubmed: 24397957
Cell Death Dis. 2013 Mar 07;4:e525
pubmed: 23470532
Neuroreport. 2009 Feb 18;20(3):301-5
pubmed: 19104456
Neuroscience. 2003;121(3):619-28
pubmed: 14568022
Invest Ophthalmol Vis Sci. 2018 Sep 4;59(11):4392-4403
pubmed: 30193320
Vis Neurosci. 1990 Jun;4(6):595-604
pubmed: 2177636
J Neurobiol. 1993 Jan;24(1):23-36
pubmed: 8419522
J Neuroinflammation. 2013 Dec 10;10:149
pubmed: 24325836
Exp Eye Res. 2005 Jul;81(1):48-56
pubmed: 15978254
J Neuroinflammation. 2012 May 14;9:92
pubmed: 22583833
Invest Ophthalmol Vis Sci. 2013 Mar 11;54(3):1805-15
pubmed: 23422829
Invest Ophthalmol Vis Sci. 2013 Feb 01;54(2):974-85
pubmed: 23307961
J Neurosci. 2017 Jun 21;37(25):6113-6124
pubmed: 28539419
Pharmacol Res. 2013 Jan;67(1):18-30
pubmed: 23085382
Eur J Neurosci. 2005 Apr;21(8):2305-9
pubmed: 15869529
Behav Brain Res. 2009 Jan 23;196(2):168-79
pubmed: 18977395
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Neurochem Int. 2010 Jul;56(8):878-85
pubmed: 20350575
Vision Res. 2009 Mar;49(6):637-47
pubmed: 19948111
J Neurobiol. 1999 Jan;38(1):116-28
pubmed: 10027567
Exp Eye Res. 2011 May;92(5):377-87
pubmed: 21354138
Exp Neurol. 1988 Oct;102(1):92-101
pubmed: 3181354
Invest Ophthalmol Vis Sci. 2015 Sep;56(10):6095-112
pubmed: 26393669
Front Neurosci. 2017 Apr 26;11:235
pubmed: 28491019
Exp Eye Res. 2018 May;170:40-50
pubmed: 29452106
Prog Brain Res. 2015;220:155-72
pubmed: 26497789